In investigations regarding hepatic ischemia—reperfusion injury, Eritoran, a crucial TLR4 antagonist, mitigates liver inflammation and cellular impairment through the blockade of the HMGB1—TLR4 axis [367]. This evidence concerns the gene TLR4 and ischemia.